Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCUL – Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.
OCUL
$6.98
Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $1,109,973,504.00
EPSttm : -1.22
finviz dynamic chart for OCUL
Ocular Therapeutix, Inc.
$6.98
0.29%
$0.02

Float Short %

9.58

Margin Of Safety %

Put/Call OI Ratio

0.15

EPS Next Q Diff

EPS Last/This Y

0.01

EPS This/Next Y

0.03

Price

7

Target Price

17.58

Analyst Recom

1.08

Performance Q

-18.03

Relative Volume

1.5

Beta

1.52

Ticker: OCUL




22 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-05OCUL7.160.120.2627583
2025-03-06OCUL7.340.120.0126719
2025-03-07OCUL7.530.120.1526804
2025-03-10OCUL7.640.120.0026732
2025-03-11OCUL8.510.122.3026685
2025-03-12OCUL8.430.140.3227266
2025-03-13OCUL7.880.150.0327784
2025-03-14OCUL7.720.150.0027711
2025-03-17OCUL7.950.150.0127861
2025-03-18OCUL7.440.150.0027901
2025-03-19OCUL7.690.150.4227849
2025-03-20OCUL7.430.140.5027854
2025-03-21OCUL7.520.143.7827854
2025-03-24OCUL7.610.150.0624220
2025-03-25OCUL7.510.140.0224322
2025-03-26OCUL7.670.140.6324548
2025-03-27OCUL7.740.140.1324549
2025-03-28OCUL7.570.140.0024622
2025-03-31OCUL7.320.143.0924648
2025-04-01OCUL6.530.140.3924690
2025-04-02OCUL7.330.141.2424936
2025-04-03OCUL7.010.152.4024959
DateSymbolLastP/C OIP/C VolTotal OI
22 items Current Page1 of 1




22 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-05OCUL7.1637.1- -1.07
2025-03-06OCUL7.35-16.7- -1.07
2025-03-07OCUL7.54-16.7- -1.22
2025-03-10OCUL7.65-16.7- -1.22
2025-03-11OCUL8.52-16.7- -1.22
2025-03-12OCUL8.44-16.7- -1.22
2025-03-13OCUL7.88-16.7- -1.22
2025-03-14OCUL7.72-16.7- -1.22
2025-03-17OCUL7.94-16.7- -1.22
2025-03-18OCUL7.45-16.7- -1.22
2025-03-19OCUL7.70-16.7- -1.22
2025-03-20OCUL7.44-16.7- -1.22
2025-03-21OCUL7.52-16.7- -1.22
2025-03-24OCUL7.62-16.7- -1.21
2025-03-25OCUL7.53-16.7- -1.21
2025-03-26OCUL7.67-16.7- -1.21
2025-03-27OCUL7.74-16.7- -1.21
2025-03-28OCUL7.58-16.7- -1.21
2025-03-31OCUL7.33-16.7- -1.21
2025-04-01OCUL6.54-16.7- -1.21
2025-04-02OCUL7.34-16.7- -1.21
2025-04-03OCUL7.00-16.7- -1.21
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
22 items Current Page1 of 1




22 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-05OCUL-0.30-5.758.76
2025-03-06OCUL-0.30-5.758.66
2025-03-07OCUL-0.30-5.758.66
2025-03-10OCUL-0.30-5.738.66
2025-03-11OCUL-0.30-5.738.66
2025-03-12OCUL-0.30-5.739.00
2025-03-13OCUL-0.30-5.739.00
2025-03-14OCUL-0.30-5.739.00
2025-03-17OCUL-0.30-5.739.00
2025-03-18OCUL-0.30-5.739.00
2025-03-19OCUL-0.30-5.739.00
2025-03-20OCUL-0.30-5.739.00
2025-03-21OCUL-0.30-5.739.00
2025-03-24OCUL-0.30-5.739.00
2025-03-25OCUL-0.30-5.739.00
2025-03-26OCUL-0.30-5.739.58
2025-03-27OCUL-0.30-5.739.58
2025-03-28OCUL-0.30-5.739.58
2025-03-31OCUL-0.30-5.749.58
2025-04-01OCUL-0.30-5.749.58
2025-04-02OCUL-0.30-5.749.58
2025-04-03OCUL-0.30-5.749.58
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
22 items Current Page1 of 1

Last Quarter Act. EPS

-0.29

Avg. EPS Est. Current Quarter

-0.28

Avg. EPS Est. Next Quarter

-0.29

Insider Transactions

-0.3

Institutional Transactions

-5.74

Beta

1.52

Average Sales Estimate Current Quarter

17

Average Sales Estimate Next Quarter

17

Fair Value

Quality Score

44

Growth Score

48

Sentiment Score

12

Actual DrawDown %

71.2

Max Drawdown 5-Year %

-90.9

Target Price

17.58

P/E

Forward P/E

PEG

P/S

17.47

P/B

3.5

P/Free Cash Flow

EPS

-1.26

Average EPS Est. Cur. Y​

-1.21

EPS Next Y. (Est.)

-1.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-303.67

Relative Volume

1.5

Return on Equity vs Sector %

-81.2

Return on Equity vs Industry %

-68.3

EPS 1 7Days Diff

-0.2

EPS 1 30Days Diff

-0.18

EBIT Estimation

Ocular Therapeutix, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 274
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading